Drugs / PRT543
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03886831 | Feb 2019 → Nov 2022 | acute myeloid leukemia, adenoid cystic carcinoma, chronic myelomonocytic leukemia, diffuse large B-cell lymphoma +4 | Prelude Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Prelude Therapeutics | Results Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics preludetx.com ↗
We are also encouraged by the preliminary clinical activity observed with both molecules in multiple tumor types, including durable responses in cancers with high unmet need. |
| 2021-03-16 | Prelude Therapeutics | Results Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update preludetx.com ↗
The Company today announced that the dose escalation portion of the Phase 1 trial of its lead product candidate, PRT543, is now complete, and that a recommended expansion dose with adequate safety, pharmacokinetics, and target engagement profile has been established. |
| 2020-11-10 | Prelude Therapeutics | Results Prelude Therapeutics Announces Third Quarter 2020 Financial Results preludetx.com ↗
Durable Complete Response Ongoing in HRD+ High Grade Serous Ovarian Cancer Patient in Phase 1 Trial of PRT543 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Prelude Therapeutics | Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics preludetx.com ↗ |
| 2021-03-16 | Prelude Therapeutics | Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update preludetx.com ↗ |
| 2020-11-10 | Prelude Therapeutics | Prelude Therapeutics Announces Third Quarter 2020 Financial Results preludetx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT543 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03886831 ↗ |
| Action | Inhibit | “PRT543, a protein arginine methyltransferase 5 inhibitor” PMID 38118249 ↗ Dec 2023 |
| Route | Oral | “PRT543 will be administered orally” NCT03886831 ↗ |
| Target | MYB | “PRT543, a protein arginine methyltransferase 5 inhibitor that downregulates NOTCH1 and MYB signalling in tumours” PMID 38118249 ↗ Dec 2023 |
| Target | NOTCH1 | “PRT543, a protein arginine methyltransferase 5 inhibitor that downregulates NOTCH1 and MYB signalling in tumours” PMID 38118249 ↗ Dec 2023 |